Abstract
TP53-altered myelodysplastic syndrome with excess blasts and TP53-altered acute myeloid leukemia should be considered under one unifying classification term for their study in clinical trials. Ultimately, such a unification would simplify the screening processes for clinical trials and allow a focus on treating the patient for a genetically defined disorder rather than one based on an arbitrary blast threshold.
Original language | English (US) |
---|---|
Pages (from-to) | 175-180 |
Number of pages | 6 |
Journal | cancer |
Volume | 129 |
Issue number | 2 |
DOIs | |
State | Published - Jan 15 2023 |
Funding
The University of Texas MD Anderson Cancer Center is supported by the National Institutes of Health (grant P30 CA016672).
Keywords
- TP53
- acute myeloid leukemia (AML)
- cutoff
- excess blasts
- myelodysplastic syndrome (MDS)
- p53
ASJC Scopus subject areas
- Oncology
- Cancer Research